Cystathionine γ-Lyase Identified as a Key Regulator of Memory and Learning
January 1, 2026
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Cayston
Synonyms :
aztreonam inhalation
Class :
Monobactams
Brand Name :
Cayston
Synonyms :
aztreonam inhalation
Class :
Monobactams
Dosage Forms & Strengths
Solution for inhalation
75mg/single-use vial
Indicated for the patients to better the respiratory symptoms of cystic fibrosis caused due to Pseudomonas aeruginosa
75 mg through inhalation every 8 hours for 28 days
Take the drug with an Alterna nebulizer only
Do not repeat 28 days post-completion
Administer the dose at a minimum interval of 4 hours
Take bronchodilator before administration
Short-acting beta agonists should be taken 15 min-4 hours before the drug, or long-acting ones 30 min-12 hours before
Dosage Forms & Strengths
Solution for inhalation
75mg/single-use vial
Indicated for the patients to better the respiratory symptoms of cystic fibrosis caused due to Pseudomonas aeruginosa
For>7 years- 75 mg through inhalation every 8 hours for 28 days
Take the drug with an Alterna nebulizer only
Do not repeat 28 days post-completion
Administer the dose at a minimum interval of 4 hours
Take bronchodilator before administration
Short-acting beta agonists should be taken 15 min-4 hours before the drug, or long-acting ones 30 min-12 hours before If administering mucolytics, take them bronchodilators before aztreonam
Refer to the adult dosing
Actions and Spectrum:
Actions:
aztreonam belongs to the class of antibiotics known as monobactams. It inhibits bacterial cell wall synthesis. Specifically, aztreonam binds to and inhibits penicillin-binding proteins (PBPs) located on the bacterial cell wall. This results in the inhibition of peptidoglycan synthesis, leading to cell wall damage and bacterial cell death.
Spectrum:
aztreonam inhalation is primarily effective against Gram-negative bacteria, including Pseudomonas aeruginosa. It has limited or no activity against Gram-positive bacteria and anaerobic organisms. Therefore, aztreonam inhalation is most commonly used to treat respiratory infections caused by susceptible Gram-negative bacteria, particularly Pseudomonas aeruginosa, in patients with cystic fibrosis.
Frequency defined
>25%
Cough (54%)
10-25%
Pharyngolaryngeal pain (12%)
Pyrexia (13%)
Nasal congestion (16%)
Wheezing (16%)
1-10%
Chest discomfort (8%)
Bronchospasm (3%)
Rash (2%)
Abdominal pain (7%)
Vomiting (6%)
Black Box Warning:
None
Contraindication/Caution:
Contraindications
Cautions
Pregnancy consideration:
Insufficient data is available.
Breastfeeding warnings:
A small amount of the drug is excreted in the breast milk.
Pregnancy category:
Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: No data is available for the drug under this category.
Pharmacology:
aztreonam inhalation is a medication used to treat respiratory tract infections caused by certain bacteria in patients with cystic fibrosis. It belongs to a class of antibiotics known as monobactams. aztreonam inhibits bacterial cell wall synthesis by binding to and inactivating penicillin-binding proteins (PBPs), enzymes in constructing the bacterial cell wall.
Pharmacodynamics:
aztreonam exhibits time-dependent killing, meaning its antibacterial activity depends on the exposure duration to effective drug concentrations. Maintaining adequate drug levels in the lungs for a sufficient period is essential to maximize its bactericidal effect.
Pharmacokinetics:
Absorption
The peak plasma concentration is achieved in 1 hour
The drug shows low systemic absorption
Distribution
The bound protein is 56%
Metabolism
The drug is metabolized in the liver
Elimination and Excretion
The drug is excreted 60-70% in urine and 13-15% in feces
Administration:
aztreonam inhalation is administered using a nebulizer or inhaler to deliver the medication directly into the lungs. aztreonam inhalation is available as a solution that needs to be converted into an aerosol for inhalation. It is typically used with a nebulizer that changes the liquid medication into a fine mist that can be inhaled.
Patient information leaflet
Generic Name: aztreonam inhalation
Pronounced: az-TREE-oh-nam
Why do we use aztreonam inhalation?
aztreonam inhalation is specifically used to treat respiratory tract infections caused by Gram-negative bacteria, particularly Pseudomonas aeruginosa, in patients with cystic fibrosis.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
